Merck could turn to private equity to finance clinical trials

The firm is looking to team up with external investors, such as private equity houses, to raise capital for clinical trials, head of pharmaceutical and consumer health divisions Stefan Oschmann told the Financial Times.

Darmstadt-based Merck aims to raise around half of the capital needed for a clinical trial for its experimental medicines, with a late-stage trial for a cancer drug costing an estimated €150-400m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Germany